SubHero Banner

Epclusa® (sofosbuvir/velpatasvir) – Expanded indication, New strength

March 19, 2020 - The FDA announced the approval of Gilead’s Epclusa (sofosbuvir/velpatasvir), for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection:

Download PDF